Nephromag (Buffered Phosphate Solution | Mertiatide)

Mertiatide, the active ingredient in Nephromag, is a buffered phosphate solution presented as an intravenous formulation for parenteral use. It is manufactured in the European Union and is used in clinical environments where controlled phosphate administration is needed, such as renal support or electrolyte management.

GNH USA supplies Nephromag as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for import and distribution, ensuring patient safety and product integrity.

Nephromag (Mertiatide) is a buffered phosphate solution used in clinical situations that require intravenous phosphate supplementation.

Electrolyte imbalance: helps restore phosphate levels in patients with hypophosphatemia. Renal replacement therapy: provides phosphate during dialysis procedures. Post‑operative care: supports phosphate homeostasis after major surgery. Critical care: used in intensive care units for patients with severe metabolic disturbances. Bone metabolism disorders: adjunct in management of conditions with phosphate deficiency.

Nephromag may be associated with infusion‑related adverse reactions and metabolic disturbances.

Common Side Effects: - Transient hyperphosphatemia: mild elevation of serum phosphate that resolves after infusion. - Local irritation: pain or erythema at the IV site. - Nausea: mild nausea during or after infusion. - Headache: occasional headache post‑infusion. - Hypotension: transient drop in blood pressure during administration.

Serious or Rare Side Effects: - Severe hyperphosphatemia: marked increase in serum phosphate leading to calcium‑phosphate precipitation. - Allergic reaction: anaphylaxis or severe hypersensitivity requiring emergency treatment. - Metabolic acidosis: significant pH shift due to buffering agents. - Renal failure exacerbation: worsening kidney function in susceptible patients.

Nephromag requires careful patient assessment and monitoring to minimise risks. - Assess serum phosphate: measure baseline levels before infusion. - Monitor calcium: watch for calcium‑phosphate precipitation. - Renal function: evaluate kidney function prior to use. - Pregnancy and lactation: use only if benefits outweigh risks. - Infusion rate: administer slowly to reduce risk of hyperphosphatemia. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Nephromag can interact with several agents that affect phosphate balance or precipitation risk.

Major Interactions (Avoid): - Calcium‑containing solutions: concurrent infusion can cause calcium‑phosphate precipitation. - Aluminum‑containing antacids: may bind phosphate and reduce efficacy. - High‑dose vitamin D: can exacerbate hyperphosphatemia.

Moderate Interactions (Monitor Closely): - Loop diuretics: may increase phosphate loss, requiring dose adjustment. - ACE inhibitors or ARBs: monitor renal function and electrolyte balance. - Parenteral nutrition: adjust phosphate content to avoid overload.